Lieke Lamont
Facility Manager
- Name
- Dr. L. Lamont
- Telephone
- +31 71 527 2727
- l.lamont@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-2779-124X
Facility Manager
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Analytical Biosciences
- Zhang Z., Karu N., Kindt A.S.D., Singh M., Lamont L., Gammeren A.J. van, Ermens A.A.M., Harms A.C., Lutzen P., Vermeulen R.C.H, Dik W.A., Langerak A.W. , Velden V.H.J. van der & Hankemeier T. (2024), Association of altered plasma lipidome with disease severity in COVID-19 patients, Biomolecules 14(3): 296.
- Vanmaele A., Bouwens E., Hoeks S.E., Kindt A., Lamont L., Fioole B., Budde R.P.J., Raa S. ten, Hussain B., Oliveira-Pinto J., Ijpma A.S., Lier F. van, Akkerhuis K.M.,Majoor-Krakauer D.F., Bruin J. L. de, Hankemeier T., Rijke Y. de, Verhagen H.J.M., Boersma E. & Kardys I. (2024), Targeted plasma multi-omics propose glutathione, glycine and serine as biomarkers for abdominal aortic aneurysm growth on serial CT scanning, Atherosclerosis 398: 118620.
- Karu N., Kindt A., Lamont L., Gammeren A.J. van, Ermens A.A.M., Harms A.C., Portengen L., Vermeulen R.C.H. Dik W.A., Langerak A.W., Velden V.H.J. van der & Hankemeier T. (2022), Plasma oxylipins and their precursors are strongly associated with COVID-19 severity and with immune response markers, Metabolites 12(7): 619.